Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.12 USD
Change Today -0.05 / -4.27%
Volume 1.5M
As of 5:20 PM 06/2/15 All times are local (Market data is delayed by at least 15 minutes).

sophiris bio inc (SPHS) Snapshot

Open
$1.29
Previous Close
$1.17
Day High
$1.29
Day Low
$1.11
52 Week High
09/10/14 - $3.34
52 Week Low
02/4/15 - $0.42
Market Cap
18.9M
Average Volume 10 Days
4.0M
EPS TTM
$-1.59
Shares Outstanding
16.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SOPHIRIS BIO INC (SPHS)

Related News

No related news articles were found.

sophiris bio inc (SPHS) Related Businessweek News

No Related Businessweek News Found

sophiris bio inc (SPHS) Details

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company’s primary product candidate is PRX302, which is in Phase III clinical trial for treatment for the symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 and other products for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California.

9 Employees
Last Reported Date: 05/15/15
Founded in 2002

sophiris bio inc (SPHS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $450.9K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $303.9K
Chief Operating Officer and Head of Research ...
Total Annual Compensation: $350.1K
Compensation as of Fiscal Year 2014.

sophiris bio inc (SPHS) Key Developments

Sophiris Bio, Inc. Enrolls First Patients in Phase 2a Proof of Concept Prostate Cancer Study

Sophiris Bio, Inc. announced that the first patients have been dosed in a Phase 2a proof of concept trial of PRX302 as a treatment for localized low to intermediate risk prostate cancer. The Phase 2a proof of concept study is a single-center, open-label study that will enroll approximately 20 patients. Previously obtained multi-parametric magnetic resonance imaging (mpMRI) of tumor lesions in each patient’s prostate, mapped to real-time three-dimensional transrectal ultrasound (TRUS), will be used in the study to guide the injection of PRX302 to treat a single, histological-proven, clinically significant lesion area in each patient’s prostate. Although the primary objective of the study is safety and tolerability, the key efficacy variable is the change in the treated clinically significant lesion on biopsy after six months. PRX302 has the potential to provide a focal targeted therapy for the ablation of localized prostate cancer while potentially avoiding many of the complications and side effects associated with whole gland radical treatments. The increasing use of multi-parametric magnetic resonance imaging (mpMRI) and advances in mapping previously obtained mpMRI images with live 3D ultrasound images enable the physician to more accurately locate tumors within the prostate when taking biopsies. This increases the accuracy with which men with clinically significant lesions are identified. It also enables the injection of PRX302 directly into previously identified clinically significant tumors located within the prostate. The targeted focal treatment of prostate cancer is in line with current treatments for solid tumors, such as breast or liver, where the goal is to remove the tumor and preserve as much of the organ as possible.

Sophiris Bio Inc. Announces Unaudited Consolidated Financial Results for the Three Months Ended March 31, 2015

Sophiris Bio Inc. announced unaudited consolidated financial results for the three months ended March 31, 2015. The Company reported a net loss of $4.3 million or $0.26 per share for the three months ended March 31, 2015 compared to a net loss of $8.5 million or $0.52 per share for the three months ended March 31, 2014. Research and development expenses were $3.1 million for the three months ended March 31, 2015 compared to $6.8 million for the three months ended March 31, 2014. The decrease in research and development costs are attributable to a decrease in the costs associated with the Company's Phase 3 PLUS- 1 clinical trial of PRX302 and costs associated with the manufacturing activities for PRX302. This decrease is offset by an increase in start-up costs associated with the Company's Phase 2a proof of concept trial for localized low to intermediate risk prostate cancer.

Sophiris Bio, Inc. Presents at 5th LD Micro Invitational Conference, Jun-02-2015 11:30 AM

Sophiris Bio, Inc. Presents at 5th LD Micro Invitational Conference, Jun-02-2015 11:30 AM. Venue: Luxe Sunset Boulevard Hotel, 11461 Sunset Blvd, Los Angeles, CA 90049, United States. Speakers: Randall E. Woods, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SPHS:US $1.12 USD -0.05

SPHS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SPHS.
View Industry Companies
 

Industry Analysis

SPHS

Industry Average

Valuation SPHS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SOPHIRIS BIO INC, please visit www.sophiris.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.